Breast Implant-associated Anaplastic Large Cell Lymphoma: An Evidence-based Systematic Review
Conclusions:
The clinical knowledge of BIA-ALCL has evolved rapidly over the last several years with major advances in diagnosis and treatment, including en bloc resection as the standard of care. Despite a limited number of high-quality clinical studies comprised mainly of Level III and Level V evidence, current evidence aligns with established NCCN consensus guidelines. When diagnosed and treated in accordance with NCCN guidelines, BIA-ALCL carries an excellent prognosis.
Source: Annals of Surgery - Category: Surgery Tags: META-ANALYSES Source Type: research
More News: Breast Augmentation | Cancer | Cancer & Oncology | Databases & Libraries | Lymphoma | Plastic Surgery | Study | Surgery